BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 27707605)

  • 1. Cyclic peptide-based potent and selective SIRT1/2 dual inhibitors harboring N
    Chen D; Zheng W
    Bioorg Med Chem Lett; 2016 Nov; 26(21):5234-5239. PubMed ID: 27707605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A bicyclic pentapeptide-based highly potent and selective pan-SIRT1/2/3 inhibitor harboring N
    Li R; Yan L; Sun X; Zheng W
    Bioorg Med Chem; 2020 Apr; 28(7):115356. PubMed ID: 32067892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simple N(ε)-thioacetyl-lysine-containing cyclic peptides exhibiting highly potent sirtuin inhibition.
    Huang Y; Liu J; Yan L; Zheng W
    Bioorg Med Chem Lett; 2016 Mar; 26(6):1612-1617. PubMed ID: 26874402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N(epsilon)-Modified lysine containing inhibitors for SIRT1 and SIRT2.
    Huhtiniemi T; Suuronen T; Lahtela-Kakkonen M; Bruijn T; Jääskeläinen S; Poso A; Salminen A; Leppänen J; Jarho E
    Bioorg Med Chem; 2010 Aug; 18(15):5616-25. PubMed ID: 20630764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human SIRT3 tripeptidic inhibitors containing N(ε)-thioacetyl-lysine.
    Chen B; Wang J; Huang Y; Zheng W
    Bioorg Med Chem Lett; 2015 Sep; 25(17):3481-7. PubMed ID: 26220157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel thiourea-based sirtuin inhibitory warheads.
    Zang W; Hao Y; Wang Z; Zheng W
    Bioorg Med Chem Lett; 2015 Aug; 25(16):3319-24. PubMed ID: 26081291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N(epsilon)-thioacetyl-lysine-containing tri-, tetra-, and pentapeptides as SIRT1 and SIRT2 inhibitors.
    Kiviranta PH; Suuronen T; Wallén EA; Leppänen J; Tervonen J; Kyrylenko S; Salminen A; Poso A; Jarho EM
    J Med Chem; 2009 Apr; 52(7):2153-6. PubMed ID: 19296597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism-based inhibition of Sir2 deacetylases by thioacetyl-lysine peptide.
    Smith BC; Denu JM
    Biochemistry; 2007 Dec; 46(50):14478-86. PubMed ID: 18027980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nepsilon-thioacetyl-lysine: a multi-facet functional probe for enzymatic protein lysine Nepsilon-deacetylation.
    Fatkins DG; Monnot AD; Zheng W
    Bioorg Med Chem Lett; 2006 Jul; 16(14):3651-6. PubMed ID: 16697640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substrate specificity of SIRT1-catalyzed lysine Nepsilon-deacetylation reaction probed with the side chain modified Nepsilon-acetyl-lysine analogs.
    Jamonnak N; Hirsch BM; Pang Y; Zheng W
    Bioorg Chem; 2010 Feb; 38(1):17-25. PubMed ID: 19914676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bivalent SIRT1 inhibitors.
    Wang J; Zang W; Liu J; Zheng W
    Bioorg Med Chem Lett; 2017 Jan; 27(2):180-186. PubMed ID: 27964881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a cell-active non-peptide sirtuin inhibitor containing N-thioacetyl lysine.
    Suzuki T; Asaba T; Imai E; Tsumoto H; Nakagawa H; Miyata N
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5670-2. PubMed ID: 19700324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Finding Potent Sirt Inhibitor in Coffee: Isolation, Confirmation and Synthesis of Javamide-II (N-Caffeoyltryptophan) as Sirt1/2 Inhibitor.
    Park JB
    PLoS One; 2016; 11(3):e0150392. PubMed ID: 26986569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclic Tripeptide-based Potent and Selective Human SIRT5 Inhibitors.
    Jiang Y; Zheng W
    Med Chem; 2020; 16(3):358-367. PubMed ID: 31161996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Selective Cyclic Peptidic Human SIRT5 Inhibitor.
    Liu J; Huang Y; Zheng W
    Molecules; 2016 Sep; 21(9):. PubMed ID: 27626398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of human sirtuins by in situ generation of an acetylated lysine-ADP-ribose conjugate.
    Asaba T; Suzuki T; Ueda R; Tsumoto H; Nakagawa H; Miyata N
    J Am Chem Soc; 2009 May; 131(20):6989-96. PubMed ID: 19413317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclic Peptide-Based Sirtuin Substrates.
    Chen D; Yan L; Zheng W
    Molecules; 2019 Jan; 24(3):. PubMed ID: 30682801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclic peptide-based potent human SIRT6 inhibitors.
    Liu J; Zheng W
    Org Biomol Chem; 2016 Jul; 14(25):5928-35. PubMed ID: 27248480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Substituting N(epsilon)-thioacetyl-lysine for N(epsilon)-acetyl-lysine in peptide substrates as a general approach to inhibiting human NAD(+)-dependent protein deacetylases.
    Fatkins DG; Zheng W
    Int J Mol Sci; 2008 Jan; 9(1):1-11. PubMed ID: 19325715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N(epsilon)-methanesulfonyl-lysine as a non-hydrolyzable functional surrogate for N(epsilon)-acetyl-lysine.
    Jamonnak N; Fatkins DG; Wei L; Zheng W
    Org Biomol Chem; 2007 Mar; 5(6):892-6. PubMed ID: 17340003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.